IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

FDA issues import alert against Ranbaxy plant

7:28 AM MDT | September 17, 2013 | Deepti Ramesh

On 16 September, FDA issued an import alert for a Ranbaxy Laboratories (Gurgaon, India) facility at Mohali, India, for violating US drug cGMP requirements. Under the alert, US officials may detain at the US border drug products manufactured at the Mohali facility, and the company will remain on the import alert until it complies with cGMP, FDA says. FDA says it does not anticipate that this action will cause a supply disruption or shortage of drugs in the United States. FDA inspections, in September and December 2012, identified significant cGMP violations...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa